The Journal of Heart and Lung Transplantation
Volume 29, Issue 9 , Pages 1014-1020 , September 2010

Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis

  • Dimitra Mitsani, MD

      Affiliations

    • Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
    • ,
  • M. Hong Nguyen, MD

      Affiliations

    • Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
    • ,
  • Eun J. Kwak, MD

      Affiliations

    • Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
    • ,
  • Fernanda P. Silveira, MD, MS

      Affiliations

    • Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
    • ,
  • Aniket Vadnerkar, MD

      Affiliations

    • Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
    • ,
  • Joseph Pilewski, MD

      Affiliations

    • Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
    • ,
  • Maria Crespo, MD

      Affiliations

    • Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
    • ,
  • Yoshiya Toyoda, MD, PhD

      Affiliations

    • Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA
    • ,
  • Christian Bermudez, MD

      Affiliations

    • Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA
    • ,
  • Cornelius J. Clancy, MD

      Affiliations

    • Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
    • Department of Medicine, Pittsburgh VA Healthcare System, Pittsburgh, PA
    • Corresponding Author InformationReprint requests: Cornelius J. Clancy, MD, University of Pittsburgh, Infectious Diseases, 3550 Terrace St, Scaife Hall, Ste. 871, Pittsburgh, PA 15261. Telephone: 412-383-5193. Fax: 412-648-8455

References 

  1. Ettinger NA, Bailey TC, Trulock EP, et al. Cytomegalovirus infection and pneumonitis (Impact after isolated lung transplantation. Washington University Lung Transplant Group). Am Rev Respir Dis. 1993;147:1017–1023
  2. Alexander BD, Tapson VF. Infectious complications of lung transplantation. Transpl Infect Dis. 2001;3:128–137
  3. Zamora MR. Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation. Transpl Infect Dis. 2001;3(suppl 2):49–56
  4. Duncan AJ, Dummer JS, Paradis IL, et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant. 1991;10:638–644discussion 45-6
  5. Duncan SR, Paradis IL, Yousem SA, et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis. 1992;146:1419–1425
  6. Duncan SR, Grgurich WF, Iacono AT, et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med. 1994;150:146–152
  7. Gerbase MW, Dubois D, Rothmeier C, Spiliopoulos A, Wunderli W, Nicod LP. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation. Chest. 1999;116:1265–1272
  8. Gutierrez CA, Chaparro C, Krajden M, Winton T, Kesten S. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin. Chest. 1998;113:924–932
  9. Soghikian MV, Valentine VG, Berry GJ, Patel HR, Robbins RC, Theodore J. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant. 1996;15:881–887
  10. Speich R, Thurnheer R, Gaspert A, Weder W, Boehler A. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. Transplantation. 1999;67:315–320
  11. Weill D, Lock BJ, Wewers DL, et al. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction. Am J Transplant. 2003;3:492–496
  12. Wreghitt TG, Abel SJ, McNeil K, et al. Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients. Transpl Int. 1999;12:254–260
  13. Valentine VG, Weill D, Gupta MR, et al. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation. J Heart Lung Transplant. 2008;27:875–881
  14. Brumble LM, Milstone AP, Loyd JE, et al. Prevention of cytomegalovirus infection and disease after lung transplantation: results using a unique regimen employing delayed ganciclovir. Chest. 2002;121:407–414
  15. Couchoud C. Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation. Cochrane Database Syst Rev. 2000;CD001320
  16. Maurer JR, Snell G, deHoyos A, Kesten S, Winton T. Outcomes of lung transplantation using three different cytomegalovirus prophylactic regimens. Transplant Proc. 1993;25:1434–1435
  17. Hertz MI, Jordan C, Savik SK, et al. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. J Heart Lung Transplant. 1998;17:913–920
  18. Kelly J, Hurley D, Raghu G. Comparison of the efficacy and cost effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients. J Heart Lung Transplant. 2000;19:355–359
  19. Bhorade SM, Sandesara C, Garrity ER, et al. Quantification of cytomegalovirus (CMV) viral load by the hybrid capture assay allows for early detection of CMV disease in lung transplant recipients. J Heart Lung Transplant. 2001;20:928–934
  20. Monforte V, Roman A, Gavalda J, et al. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients. Transplant Proc. 2005;37:4039–4042
  21. Cochrane AB. Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients. Am J Health Syst Pharm. 2006;63:S17–S21
  22. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4:611–620
  23. Zamora MR, Nicolls MR, Hodges TN, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant. 2004;4:1635–1642
  24. Humar A, Kumar D, Preiksaitis J, et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant. 2005;5:1462–1468
  25. Jaksch P, Zweytick B, Kerschner H, et al. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy. J Heart Lung Transplant. 2009;28:670–675
  26. Monforte V, Lopez C, Santos F, et al. A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients. Am J Transplant. 2009;9:1134–1141
  27. Chmiel C, Speich R, Hofer M, et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis. 2008;46:831–839
  28. Cytomegalovirus. American Journal of Transplantation. 2004;4:51–58
  29. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant. 2009;9:S78–S86
  30. Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. Pharmacotherapy. 2004;24:1323–1330
  31. Gruber SA, Garnick J, Morawski K, et al. Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus. Clin Transplant. 2005;19:273–278
  32. Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant. 2003;3:731–735
  33. Perrottet N, Csajka C, Pascual M, et al. Population pharmacokinetics of ganciclovir in solid organ transplant recipients receiving oral valganciclovir. Antimicrob Agents Chemother. 2009;53:3017–3023
  34. Wiltshire H, Hirankarn S, Farrell C, et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet. 2005;44:495–507
  35. Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation. 2005;79:1477–1483
  36. Kalil AC, Freifeld AG, Lyden ER, Stoner JA. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS One. 2009;4:e5512
  37. Kijpittayarit-Arthurs S, Eid AJ, Kremers WK, et al. Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients. J Heart Lung Transplant. 2007;26:1019–1024
  38. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis. 2002;185:20–27
  39. Li F, Kenyon KW, Kirby KA, Fishbein DP, Boeckh M, Limaye AP. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis. 2007;45:439–447
  40. Reddy AJ, Zaas AK, Hanson KE, Palmer SM. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome. J Heart Lung Transplant. 2007;26:1286–1292
  41. Bando K, Paradis IL, Similo S, et al. Obliterative bronchiolitis after lung and heart-lung transplantation (An analysis of risk factors and management). J Thorac Cardiovasc Surg. 1995;110:4–13discussion 14
  42. Johanssson I, Martensson G, Andersson R. Cytomegalovirus and long-term outcome after lung transplantation in Gothenburg, Sweden. Scand J Infect Dis. 2010;42:129–136
  43. Girgis RE, Tu I, Berry GJ, et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant. 1996;15:1200–1208
  44. Manuel O, Kumar D, Moussa G, et al. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation. 2009;87:719–725
  45. Tamm M, Aboyoun CL, Chhajed PN, Rainer S, Malouf MA, Glanville AR. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2004;170:1120–1123
  46. Ruttmann E, Geltner C, Bucher B, et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation. 2006;81:1415–1420
  47. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99:4357–4363

PII: S1053-2498(10)00279-2

doi: 10.1016/j.healun.2010.04.022

The Journal of Heart and Lung Transplantation
Volume 29, Issue 9 , Pages 1014-1020 , September 2010

Article Tools

* Image Usage & Resolution